Results 61 to 70 of about 7,390 (165)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis [PDF]

, 2020
Background: Recently, ocrelizumab (Ocrevus(R)) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial.
Nat, P.B. van der, Garde, E.M. van de, van de Garde, E M W, Daniels, K, Wees, P.J. van der, Hoogervorst, E L J, Biesma, D.H., Biesma, D H, Daniels, K., Hoogervorst, E.L., Afd Pharmacoepi & Clinical Pharmacology, Frequin, S T F M, Pharmacoepidemiology and Clinical Pharmacology, Frequin, S., van der Nat, P B, van der Wees, P J   +15 more
core   +3 more sources

Endocarditis following ocrelizumab in relapsing-remitting MS

, 2020
Ocrelizumab is a monoclonal anti-CD20 antibody targeting B cells, which is authorized for relapsing-remitting MS (RRMS) and active primary progressive MS.
Mügge, Andreas (Prof. Dr. med.), Gotzmann, Michael (Prof. Dr. med.), Faissner, Simon Raoul (Prof. Dr. med.), Schmidt, Stephan (Prof. Dr. med.), Schwake, Carolin (Dr. med.), Gold, Ralf (Prof. Dr. med.)   +5 more
core   +1 more source

Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross‐Sectional Study

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aims To identify a correlation between unmet needs and HL levels in people with Multiple Sclerosis (pwMS) and to evaluate how sociodemographic characteristics influence HL levels and unmet needs. Design A cross‐sectional study. Methods The study was conducted using a questionnaire including the HLS19‐Q12 to assess HL and the Long‐term Unmet ...
Francesco Pastore, Barbara Forastefano, Valentina Simonetti, Tommaso Guerra, Giancarlo Cicolini, Pietro Iaffaldano, Dania Comparcini   +6 more
wiley   +1 more source

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Annals of Clinical and Translational Neurology
Objective No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available.
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio, Matilde Inglese, Matteo Foschi, Francesco Patti, Franco Granella, Silvia Romano, Paola Cavalla, Giovanna De Luca, Paolo Gallo, Paolo Bellantonio, Antonio Gallo, Sara Montepietra, Alessia Di Sapio, Marika Vianello, Rocco Quatrale, Daniele Spitaleri, Raffaella Clerici, Valentina Torri Clerici, Eleonora Cocco, Vincenzo Brescia Morra, Girolama Alessandra Marfia, Vincenzo Daniele Boccia, Massimo Filippi, Maria Pia Amato, Maria Trojano, the Italian MS Register   +29 more
doaj   +1 more source

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

MedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly ...
Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Shibeshih Belachew, Iain Bennett, Regine Buffels, Hideki Garren, Jian Han, Laura Julian, Julie Napieralski, Stephen L Hauser, Gavin Giovannoni   +17 more
doaj   +1 more source

Myelin Impairment and Regeneration in the Central Nervous System: Molecular Mechanisms, Diseases, and Prospective Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
Proper myelin formation is crucial for normal neural circuit function, while myelin deficiency can lead to neural circuit dysfunction and cognitive decline, notably in Alzheimer's disease and other central nervous system demyelinating disorders. This review summarizes central myelin's structure and function, demyelination biomarkers and pathological ...
Lihong Huang, Peng Cheng, Guangdong Liu, Yang Xiang, Zhen Hong, Weidong Le   +5 more
wiley   +1 more source

Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases

Health Science Reports, 2023
Background Primary‐progressive multiple sclerosis (PPMS) and relapsing‐remitting multiple sclerosis (RRMS) are two frequent multiple sclerosis (MS) subtypes that involve 10%–15% of patients. PPMS progresses slowly and is diagnosed later in life.
Priyadarshi Prajjwal, Mohammed Dheyaa Marsool Marsool, Shahnaz Asharaf, Pugazhendi Inban, Srikanth Gadam, Rukesh Yadav, Neel Vora, Varsha Nandwana, Ali Dheyaa Marsool Marsool, Omniat Amir   +9 more
doaj   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Dengue fever in a multiple sclerosis patient taking Ocrelizumab

, 2021
Dengue fever (DF) is an endemic infectious disease in tropical and subtropical regions. Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B cells, which is approved for the treatment of both relapsing-remitting multiple ...
Bollo, Luca, Trojano, Maria, Iaffaldano, Pietro, Guerra, Tommaso   +3 more
core   +1 more source